ArticleDiscover oncology2025
Mechanism of dexmedetomidine in inhibiting proliferation, migration, and invasion of esophageal squamous cell carcinoma cell through coagulation factor II receptor.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effects and mechanisms of action of dexmedetomidine (DEX) on the proliferation, migration, and invasion of esophageal squamous cell carcinoma (ESCC) cells. Network pharmacology and bioinformatics analyses identified core targets, including vascular cell adhesion molecule-1 (VCAM-1), chemokine receptor 2 (CXCR2), matrix metalloproteinases (MMPs) 1, 2, and 3, and coagulation factor II (thrombin) receptor (F2R). Among these genes, F2R was associated with poor prognosis in these patients. The experimental validation was performed using the TE13 human esophageal cell line, which were exposed to different concentrations of DEX (Experiment 1) and transfected with a lentivirus to generate a model of coagulation F2R overexpression (Experiment 2). Through a combination of techniques, including clone formation, scratching, MTT, Transwell assays, western blotting, as well as quantitative real-time PCR (qRT-PCR). Experiment 1 demonstrated DEX could significantly decreased TE13 cell proliferation, migration, and invasion abilities. Moreover, the levels of MMP1, MMP2, F2R, VCAM-1, and MMP3 proteins were significantly reduced after DEX treatment, whereas CXCR2 levels were significantly increase. Experiment 2 selected F2R as the target of DEX for mechanistic studies. DEX can reverse the malignant progression of TE13 cells overexpressing F2R. Western blotting revealed a significant decrease in the expression of F2R/ extracellular signal-regulated kinase (ERK) ERK1/2-related pathway proteins after DEX treatment (P < 0.05). The foregoing results underscore DEX can inhibit the proliferation, migration, and invasion of ESCC cells, and its mechanism of action may be related to inhibition of the F2R/ERK1/2 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.